Skip to main content

Breadcrumb

  1. Home
  2. BOOM-IBD2 Clinical Trial to Evaluate the…
  • General Information >>
  • Eligibility >>
  • Study Details >>
  • Contact Information >>

BOOM-IBD2 Clinical Trial to Evaluate the Effectiveness of Neuromodulation for Ulcerative Colitis

Published: 10/04/2024

General Information:

boomIBD2 trial logo
Click Here to Learn More »
Study Objective

The objective of the BOOM-IBD2 clinical trial is to evaluate the effectiveness of an investigational nerve stimulation (neuromodulation) device for ulcerative colitis (UC). This treatment involves implanting a small electronic device that delivers mild electrical pulses to a nerve near the tailbone. The study will assess the impact of this therapy on bowel urgency, quality of life, inflammation, and other measures over a 12-month period through a combination of in-person and virtual visits.

Phase of study
Other
RETURN TO TOP

Eligibility:

Age
Adult (18+)
Gender
Female
Male
Disease Type
Ulcerative Colitis
Severity
Mild
Moderate
Severe
Eligibility Criteria

Inclusion Criteria:

● Male or female

● 18 to 85 years of age

● Diagnosed with ulcerative colitis

● Ability and willingness to consent to participate by signing the informed consent form

● Ability to comply with the protocol and willingness to comply with all follow-up requirements

Exclusion Criteria:

● Crohn's disease, indeterminate colitis/inflammatory bowel disease-unclassified

● Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound the results of the study

● Any psychiatric or personality disorder at the discretion of the study investigator

● Any active bacterial infection with a risk of bacteremia or sepsis (e.g. presence of abscess)

● Active clostridium difficile infection of the colon

● Active cytomegalovirus (CMV) infection of the colon

● Evidence of colonic perforation

● Fulminant colitis requiring emergency surgery

● Microscopic, ischemic or infectious colitis

● Unresected neoplasia of the colon

● Colonic stricture unable to pass a colonoscope

● Current evidence of cancer in the gastrointestinal tract

● Current participation in another clinical trial

● Previous history of surgery for ulcerative colitis

● Previously implanted with a neurostimulation device or participated in a neurostimulation trial

● Inability to operate the patient programmer

RETURN TO TOP

Study Details:

Study description/explanation of participation:

The investigational nerve stimulation (neuromodulation) device is implanted in an outpatient procedure and delivers mild electrical pulses to a nerve near the tailbone. The study will last 12 months following implantation, involving 6 in-person visits and 4 virtual visits. Throughout this 12-month period, the patient will be monitored to assess the device's effectiveness.

Patient Participation Requirements:

6 in-person visits, 4 virtual visits with the following surveys/questionnaires: EQ-5D-5L Questionnaire, IBDQ, Electronic Urgency Numeric Rating Scale (UNRS), Patient Simple Ulcerative Colitis Clinical Activity Index, Work Productivity and Activity Impairment Questionnaire-UC (WPAI-UC)

Possible risks and side effects:

Potential risks of surgical implantation include, but are not limited to:

● Adverse change in bowel or urinary function

● Allergic or immune response to the implanted materials that could result in device rejections

● Change in sexual function

● Cyst

● Depression

● Device complications (e.g. device failure/malfunction; lead fracture; lead/neurostimulator migration, dislodgement, or erosion; reoperation/revision)

● Fever

● Implant site complications (e.g. dehiscence [failure of wound to heal]; discharge; ecchymosis [discoloration of skin due to bleeding beneath]; effusion [escape of fluid]; erosion; erythema [reddening of the skin]; hematoma [pooling of blood outside of a blood vessel]; hemorrhage; infection; irritation; pain; paresthesia [burning or prickling sensation, usually in the hands or feet]; seroma [a buildup of fluids where tissue has been removed])

● Infection

● Inflammation

● Insomnia

● Lack of effective therapy or loss of therapeutic effect resulting in return of baseline symptoms

● Nausea/ vomiting

● Neuromuscular complications (e.g. muscle spasms and contractions; changes in voluntary movement)

● New pain

● Skin complications (e.g. itching, rash, discoloration)

● Stimulation/sensation complication (e.g. change in sensation or magnitude of stimulation which has been described as uncomfortable (jolting or shocking) by some patients; unintended nerve activation)

● Suspected nerve injury

● Transient electrical shock

● Tenderness/ discomfort

● Weakness

RETURN TO TOP

Contact Information:

Site Locations

Columbia University 161 Fort Washington Avenue New York, New York 10032
Language: English
More Site Details
Center for Colorectal Innovation 8737 Beverly Blvd. Suite 101 West Hollywood, California 90048
Language: English
More Site Details
Great Lakes Gastroenterology 8877 Mentor Ave Mentor, Ohio 44060
Language: English
More Site Details
Hoag Hospital 500 Superior Ave Ste. 100 Newport Beach, California 92663
Language: English
More Site Details
Kansas Gastro 3121 N. Webb Road Suite 101 Wichita, Kansas 67226
Language: English
More Site Details
Minnesota Urology 6025 Lake Road Suite 200 Woodbury, Minnesota 55125
Language: English
More Site Details
Palo Alto Medical Foundation 795 El Camino Real Palo Alto, California 94301
Language: English
More Site Details
Sanford Health 1500 W 22nd St Suite 402 Sioux Falls, South Dakota 57105
Language: English
More Site Details
UNC Health - Chapel Hill 130 Mason Farm Road CB 7080 Chapel Hill, North Carolina 27599
Language: English
More Site Details
Vector Clinical Research 2851 N Tenaya Way Las Vegas, Nevada 89128
Language: English
More Site Details
Objective Health – St. Louis 12855 N Forty Dr. South Tower, Suite 295 St. Louis, Missouri 63141
More Site Details
Objective Health – Amarillo 1901 Medi Park Drive Suite 205 Amarillo, Texas 79106
More Site Details
Objective Health – Central Texas 7030 New Sanger Ave. Suite 204 Waco, Texas 76712
More Site Details
Click Here to Learn More »
RETURN TO TOP

Browser not supported

Your Internet Explorer is outdated. For optimal security settings and a better experience on our site, try switching to one of these options:

Google Chrome

Download Chrome

Firefox

Download Firefox

Safari (macOS 10.8+ only)

Download Safari